JP2022518292A5 - - Google Patents
Info
- Publication number
- JP2022518292A5 JP2022518292A5 JP2021543315A JP2021543315A JP2022518292A5 JP 2022518292 A5 JP2022518292 A5 JP 2022518292A5 JP 2021543315 A JP2021543315 A JP 2021543315A JP 2021543315 A JP2021543315 A JP 2021543315A JP 2022518292 A5 JP2022518292 A5 JP 2022518292A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025009888A JP2025081323A (ja) | 2019-01-23 | 2025-01-23 | ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796002P | 2019-01-23 | 2019-01-23 | |
| US62/796,002 | 2019-01-23 | ||
| PCT/US2020/014819 WO2020154520A1 (en) | 2019-01-23 | 2020-01-23 | Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009888A Division JP2025081323A (ja) | 2019-01-23 | 2025-01-23 | ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518292A JP2022518292A (ja) | 2022-03-14 |
| JP2022518292A5 true JP2022518292A5 (https=) | 2023-02-01 |
| JPWO2020154520A5 JPWO2020154520A5 (https=) | 2023-02-01 |
Family
ID=71735544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543315A Pending JP2022518292A (ja) | 2019-01-23 | 2020-01-23 | ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 |
| JP2025009888A Pending JP2025081323A (ja) | 2019-01-23 | 2025-01-23 | ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009888A Pending JP2025081323A (ja) | 2019-01-23 | 2025-01-23 | ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220098257A1 (https=) |
| EP (1) | EP3914701B1 (https=) |
| JP (2) | JP2022518292A (https=) |
| CN (1) | CN113490739A (https=) |
| CA (1) | CA3127357A1 (https=) |
| WO (1) | WO2020154520A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911603D0 (en) * | 2019-08-14 | 2019-09-25 | Healx Ltd | Treatment |
| EP4001923B1 (en) | 2020-11-23 | 2024-06-05 | Roche Diagnostics GmbH | Laboratory sample distribution system and laboratory automation system |
| EP4249607A1 (en) * | 2022-03-21 | 2023-09-27 | Warszawski Uniwersytet Medyczny | Panel of markers for prediction of epilepsy recurrence in patients with tuberous sclerosis and the uses thereof |
| CN121022847B (zh) * | 2025-10-31 | 2026-02-06 | 温州医科大学附属眼视光医院 | 一种敲除斑马鱼pde6a的sgRNA及其在视觉疾病中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4999255B2 (ja) * | 2001-07-10 | 2012-08-15 | レイクウッド−アメディックス，インコーポレーテッド | オリゴヌクレオチド含有薬理学的組成物およびその使用 |
| US20050164275A1 (en) * | 2002-10-18 | 2005-07-28 | Incyte Corporation | Phosphodiesterases |
| ZA200704251B (en) * | 2004-10-28 | 2008-11-26 | Celgene Corp | Methods and compositions using PDE4 modulators for treatment and management of central nervous injury |
| US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
| EP2037924A2 (en) * | 2006-07-07 | 2009-03-25 | Steven P. Govek | Bicyclic heteroaryl inhibitors of pde4 |
| EP2334180A4 (en) * | 2008-09-15 | 2013-07-03 | Univ California | RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION |
| US20130065936A1 (en) * | 2010-05-14 | 2013-03-14 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
| CA2817290A1 (en) * | 2010-11-11 | 2012-05-18 | Josef Penninger | Compounds and methods for treating pain |
| US8865723B2 (en) * | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| EP2925364A1 (en) * | 2012-11-30 | 2015-10-07 | Leo Pharma A/S | A method of inhibiting the expression of il-22 in activated t-cells |
| EP3766885B1 (en) * | 2015-06-17 | 2022-05-25 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| SG11201806383TA (en) * | 2016-02-23 | 2018-09-27 | Pfizer | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
-
2020
- 2020-01-23 EP EP20744495.1A patent/EP3914701B1/en active Active
- 2020-01-23 JP JP2021543315A patent/JP2022518292A/ja active Pending
- 2020-01-23 CA CA3127357A patent/CA3127357A1/en active Pending
- 2020-01-23 WO PCT/US2020/014819 patent/WO2020154520A1/en not_active Ceased
- 2020-01-23 CN CN202080013929.1A patent/CN113490739A/zh active Pending
- 2020-01-23 US US17/424,055 patent/US20220098257A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009888A patent/JP2025081323A/ja active Pending